Controlling multiple-drug-resistant organisms at the hospital level

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 11, 2006, Pages 1449-1455

  Ramirez, Julio A ^a,b  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antibiotic control; Drug resistance; Infection control; Methicillin resistant Staphylococcus aureus; Vancomycin resistant enterococci

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; LINEZOLID; METICILLIN; NAFCILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL FLORA; BACTERIUM CARRIER; BACTERIUM CONTAMINATION; DISINFECTION; DRUG USE; ENDOTRACHEAL INTUBATION; EPIDEMIC; HEALTH CARE COST; HIGH RISK PATIENT; HOSPITAL HYGIENE; HOSPITAL INFECTION; HOSPITAL MANAGEMENT; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION RISK; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PATHOGENESIS; PNEUMONIA; PRESCRIPTION; PYELONEPHRITIS; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ANIMALS; CLINICAL PROTOCOLS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; HOSPITALS; HUMANS; INFECTION CONTROL;

EID: 33746835252     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.11.1449     Document Type: Review

References (32)

1. WISPLINGHOFF H, BISCHOFF T, TALLENT SM, SEIFERT H, WENZEL RP, EDMOND MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. (2004)39(3):309-317.
2. LINDEN PK, KUSNE S, COLEY K, FONTES P, KRAMER DJ, PATERSON D: Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin. Infect. Dis. (2003) 37(11):e154-e160.
3. SCHWABER MJ, NAVON-VENEZIA S, KAYE KS, BEN-AMI R, SCHWARTZ D, CARMELI Y: Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. (2006) 50(4):1257-1262.
4. COSGROVE SE, CARMELI Y: The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. (2003) 36:1433-1437.
5. SHLAES DM, GERDING DN, JOHN JF et al.: Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis. (1997) 25:584-599.
6. HUGHES VM, DATTA N: Conjugative plasmids in bacteria of the 'pre-antibiotic' era. Nature (1983) 302:725-726.
7. FOURNIER PE, RICHET H: The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin. Infect. Dis. (2006) 42:692-699.
8. SAIMAN L, O'KEEFE M, GRAHAM PL III et al.: Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin. Infect. Dis. (2003) 37:1313-1319.
9. HEALY CM, HULTEN KG, PALAZZI DL, CAMPBELL JR, BAKER CJ: Emergence of new strains of methicillin-resistant Staphylococcus aureus in a neonatal intensive care unit. Clin. Infect. Dis. (2004) 39:1460-1466.
10. SEYBOLD U, KOURBATOVA EV, JOHNSON JG et al.: Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. (2006) 42:647-656.
11. PATERSON DL: 'Collateral damage' from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. (2004) 38(4):S341-S345.
12. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. (2005) 171:388.
13. KOLLEF MH, MICEK ST: Strategies to prevent antimicrobial resistance in the intensive care unit. Crit. Care Med. (2005) 33:1845-1853.
14. IBRAHIM EH, SHERMAN G, WARD S, FRASER VJ, KOLLEF MH: The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest (2000) 118:146-155.
15. NIEDERMAN MS: Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin. Infect. Dis. (2006) 42(2):S72-S81.
16. GOLDMANN DA, WEINSTEIN RA, WENZEL RP et al.: Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA (1996) 275(3):234-240.
17. MUTO CA, JERNIGAN JA, OSTROWSKY BE et al.: SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect. Control Hosp. Epidemiol.(2003) 24(5):362-386.
18. BOYCE JM, PITTET D: Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. MMWR Recomm. Rep. (2002) 51(RR-16):1-45.
19. ANDERSON DJ, ENGEMANN JJ, HARRELL J, CARMELI Y, RELLER LB, KAYE KS: Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella. Antimicrob. Agents Chemother. (2006) 50:1715-1720.
20. ARNOLD FW, NEWMAN D, SMITH S, MCDONALD LC, RAMIREZ JA: Improving antimicrobial use: longitudinal assessment of a hospital antimicrobial team including clinical pharmacist. J. Manag. Care Pharm. (2004) 10:152-158.
21. NIEDERMAN MS, MANDELL LA, ANZUETO A et al.: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. (2001) 163:1730.
22. STEVENS DL, BISNO AL, CHAMBERS HF et al.: Practice guidelines for the daignosis and management of skin and soft tissue infections. Clin. Infect. Dis. (2005) 41(10):1373-1406.
23. SOLOMKIN JS, MAZUSKI JE, BARON EJ et al.: Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Infectious Diseases Society of America. Clin. Infect. Dis. (2003) 37:997.
24. Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Infect. Control Hosp. Epidemiol. (1995) 16(2):105-113.
25. GALLAGHER EJ: How well do clinical practice guidelines guide clinical practice? Ann. Emerg. Med. (2002) 40(4):394-398.
26. MARR JJ, MOFFET HL, KUNIN CM: Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J. Infect. Dis. (1988) 157:869-876.
27. ARNOLD FW, MCDONALD C, SMITH RS, NEWMAN D, RAMIREZ JA: Improving antimicrobial use in the hospital setting by providing usage feedback to prescribing physicians. Infect. Control Hosp. Epidemiol. (2006) 27(4):378-382.
28. BURKE JD, AKHEE S, RITTER GW, RAMIREZ JA: Development of an interdisciplinary antimicrobial team: elements of success. Hosp. Pharm. (1996) 31:361-366.
29. LIPSITCH M, SAMORE MH: Antimicrobial use and antimicrobial resistance: a population perspective. Emerg. Infect. Dis. (2002) 8(4):347-354.
30. FOX BC, IMREY PB, VOIGHTS MB et al.: Infectious disease consultation and microbiologic surveillance for intensive care unit trauma patients: a pilot study. Clin. Infect. Dis. (2001) 33:1981-1989.
31. GROSS R, MORGAN AS, KINKY D et al.: Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin. Infect. Dis. (2001) 33:289-295.
32. DELISLE S, PERL TM: Antimicrobial management measures to limit resistance: a process-based conceptual framework. Crit. Care Med. (2001) 29:121-127.